Related Experiment Video

Updated: Jul 25, 2025

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.7K

Immune checkpoint inhibitor induced neurocognitive deficits in patients

Robert Zeiser1,2,3, Marco Prinz3,4,5

  • 1Department of Internal Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Brain Communications
|June 30, 2023
PubMed

Abstract:

This scientific commentary refers to 'Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity', by Farina et al. (https://doi.org/10.1093/braincomms/fcad169).

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.5K

Related Experiment Videos

Last Updated: Jul 25, 2025

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
10:10

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

12.7K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.5K

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

160
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
160

Articles linked to this work by shared authors, journal, and citation graph.

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

Bone marrow transplantation·2026

Distinct postnatal trajectories of mouse dendritic epidermal T cells and Langerhans cells independent of microbiota.

Science advances·2026

USP8 controls proteostasis pathways in B cells and multiple myeloma.

Leukemia·2026

Minute-Scale Repeated Metabolic Probing of Living Cells Enabled by Rapid Parahydrogen-Based Hyperpolarization.

Angewandte Chemie (International ed. in English)·2026

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Prion protein (PrP) profiles in blood and CSF: insights into pre-symptomatic and symptomatic prion disease.

Brain communications·2026

Genomic insights into stroke recovery: cross-phenotype associations.

Brain communications·2026

Highlights from the Brain Conference 2026.

Brain communications·2026

Elevated intron retention implicates neuroinflammation in brains of individuals with alcohol use disorder.

Brain communications·2026

Enhancing brain age estimation with structural MRI and synthesized cerebral blood volume maps.

Brain communications·2026

A vascular component to the selective vulnerability of the medial temporal lobe to tau pathology.

Brain communications·2026

A Prediction Model for Persistent Inflammation-Immunosuppression-Catabolism Syndrome in Patients with Sepsis: An Ambispective Cohort Study.

Infection and drug resistance·2026

Non-invasive risk stratification of immunoglobulin A nephropathy and crescent formation using contrast-enhanced ultrasound combined with serological markers.

Quantitative imaging in medicine and surgery·2026

Risk Stratification for Tuberculosis Reactivation in Patients Receiving Biological and Non-biological Immunomodulators: A Review of Current Literature.

The Journal of infection·2026

A pilot study of a urinary IL-8 and IL-17-based formula for discriminating Hunner-type from non-Hunner-type interstitial cystitis.

Cytokine·2026

The anti-fibrotic effects of irisolidone via peroxisome proliferator-activated receptor gamma.

Tissue & cell·2026

Impact of dietary myo-inositol supplements on immune cell distribution and cytokine expression in laying hens of two different strains.

Poultry science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us